Inhibitors

Cochlearine
Catalog No: CFN00213

Cochlearines A can significantly inhibit Cav3.1 T-type calcium channel (TTCC) and show noticeable selectivity against Cav1.2, Cav2.1, Cav2.2, and Kv11.1 (hERG) channels; and TTCC inhibitors hold great potential for the treatment of a variety of neurological disorders.

Tropacocaine
Catalog No: CFN00219

Tropacocaine has cardiovascular effects.Tropacocaine inhibits norepinephrine uptake at the concentration of 30 microM. Tropacocaine has antimuscarinic activity, it can attenuate the oxotremorine-induced inhibition of the release of acetylcholine, it can inhibit the spontaneous and veratridine-induced release of newly synthesized acetylcholine, but not via activation of presynaptic muscarinic receptors.

Scopoline
Catalog No: CFN00228

Scopoline, tropinol, ecgonine, and granatoline derivatives are therapeutic agents of the pyrrole and pyridine group. Scopoline has fungitoxic effects, it is inhibitory to Sclerotinia at similar doses to scopoletin; as scopolin is known to be less phytotoxic than ayapin and scopoletin, its accumulation may well confer head rot resistance with minimal plant damage and might be one of the bases for resistance to Sclerotinia.

Tetrahydroalstonine
Catalog No: CFN97109

Tetrahydroalstonine and Raubasine preferentially block the pressor responses of post-synaptic alpha-adrenergic receptor activation due to exogenous and endogenouse noradrenaline, respectively.

Dehydrocrenatidine
Catalog No: CFN97116

Dehydrocrenatidine is a JAK-specific inhibitor, can inhibit JAK-STAT3-dependent DU145 and MDA-MB-468 cell survival and induce cell apoptosis.